文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

眼部前药:特性与挑战。

Ocular prodrugs: Attributes and challenges.

作者信息

Kour Jagpreet, Kumari Neha, Sapra Bharti

机构信息

Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala 147001, India.

出版信息

Asian J Pharm Sci. 2021 Mar;16(2):175-191. doi: 10.1016/j.ajps.2020.08.002. Epub 2020 Sep 28.


DOI:10.1016/j.ajps.2020.08.002
PMID:33995612
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8105420/
Abstract

Ocular drug delivery is one of the most attention-grabbing and challenging endeavors among the numerous existing drug delivery systems. From a drug delivery point of view, eye is an intricate organ to investigate and explore. In spite of many limitations, advancements have been made with the intention of improving the residence time or permeation of the drug in the ocular region. Poor bioavailability of topically administered drugs is the major issue pertaining to ocular drug delivery. Several efforts have been made towards improving precorneal residence time and corneal penetration, e.g. iontophoresis, prodrugs and ion-pairing, etc. Prodrug approach (chemical approach) has been explored by the formulation scientists to optimize the physicochemical and biochemical properties of drug molecules for improving ocular bioavailability. Formulation of ocular prodrugs is a challenging task as they should exhibit optimum chemical stability as well as enzymatic liability so that they are converted into parent drug after administration at the desired pace. This review will encompass the concept of derivatization and recent academic and industrial advancements in the field of ocular prodrugs. The progression in prodrug designing holds a potential future for ophthalmic drug delivery.

摘要

眼部药物递送是众多现有药物递送系统中最引人关注且具有挑战性的领域之一。从药物递送的角度来看,眼睛是一个复杂的有待研究和探索的器官。尽管存在许多限制,但为了提高药物在眼部区域的停留时间或渗透性,已经取得了一些进展。局部给药药物的生物利用度低是眼部药物递送的主要问题。人们已经做出了多种努力来提高药物在角膜前的停留时间和角膜渗透性,例如离子导入法、前体药物和离子对法等。制剂科学家们探索了前体药物方法(化学方法),以优化药物分子的物理化学和生化性质,从而提高眼部生物利用度。眼部前体药物的制剂是一项具有挑战性的任务,因为它们应表现出最佳的化学稳定性以及酶促反应性,以便在给药后能以所需的速度转化为母体药物。本综述将涵盖衍生化的概念以及眼部前体药物领域近期的学术和产业进展。前体药物设计的进展为眼科药物递送带来了潜在的未来发展前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/e41a1c57b230/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/677464dea533/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/72dbbdf61f7e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/499581a51dbc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/2be89fcd16a7/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/9b1373439081/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/8a9148b49f6f/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/978a7d3f0fa0/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/143dabc15022/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/a2101d5550c3/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/c51a9651be30/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/e6951087695d/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/f45128b45030/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/e41a1c57b230/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/677464dea533/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/72dbbdf61f7e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/499581a51dbc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/2be89fcd16a7/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/9b1373439081/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/8a9148b49f6f/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/978a7d3f0fa0/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/143dabc15022/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/a2101d5550c3/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/c51a9651be30/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/e6951087695d/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/f45128b45030/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95e0/8105420/e41a1c57b230/gr12.jpg

相似文献

[1]
Ocular prodrugs: Attributes and challenges.

Asian J Pharm Sci. 2021-3

[2]
Enhancement of ocular drug penetration.

Crit Rev Ther Drug Carrier Syst. 1999

[3]
Recent advances in ocular drug delivery.

Drug Dev Ind Pharm. 2012-11-16

[4]
Prodrug strategies in ocular drug delivery.

Med Chem. 2012-7

[5]
Prodrugs and nanomicelles to overcome ocular barriers for drug penetration.

Expert Opin Drug Metab Toxicol. 2020-10

[6]
Ocular preparations: the formulation approach.

Drug Dev Ind Pharm. 2002-5

[7]
Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery.

Drug Dev Ind Pharm. 2008-10

[8]
Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.

Drug Test Anal. 2011-3-18

[9]
Advances in the use of prodrugs for drug delivery to the eye.

Expert Opin Drug Deliv. 2017-1

[10]
Stimuli sensitive hydrogels for ophthalmic drug delivery: A review.

Int J Pharm Investig. 2012-4

引用本文的文献

[1]
Nano-based drug delivery systems for the treatment of non-infectious uveitis.

Adv Ophthalmol Pract Res. 2024-11-12

[2]
Thermosensitive Polyhedral Oligomeric Silsesquioxane Hybrid Hydrogel Enhances the Antibacterial Efficiency of Erythromycin in Bacterial Keratitis.

Biomater Res. 2024-7-22

[3]
Advancing ophthalmic delivery of flurbiprofen via synergistic chiral resolution and ion-pairing strategies.

Asian J Pharm Sci. 2024-6

[4]
Developments in Emerging Topical Drug Delivery Systems for Ocular Disorders.

Curr Drug Res Rev. 2024

[5]
Long-Acting Ocular Injectables: Are We Looking In The Right Direction?

Adv Sci (Weinh). 2024-2

[6]
Polymer-Based Self-Assembled Drug Delivery Systems for Glaucoma Treatment: Design Strategies and Recent Advances.

Polymers (Basel). 2023-11-20

[7]
Advancements in Nanogels for Enhanced Ocular Drug Delivery: Cutting-Edge Strategies to Overcome Eye Barriers.

Gels. 2023-9-4

[8]
Profiling tear film enzymes reveals major metabolic pathways involved in the homeostasis of the ocular surface.

Sci Rep. 2023-9-14

[9]
Advances in Nanogels for Topical Drug Delivery in Ocular Diseases.

Gels. 2023-4-2

本文引用的文献

[1]
Self-Assembling Peptide Nanofiber Hydrogels for Controlled Ocular Delivery of Timolol Maleate.

ACS Biomater Sci Eng. 2017-12-11

[2]
Advances in Biodegradable Nano-Sized Polymer-Based Ocular Drug Delivery.

Polymers (Basel). 2019-8-20

[3]
Dendrimers: From Design to Application-A Progress Report.

Angew Chem Int Ed Engl. 1999-4-1

[4]
Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases.

Pharmaceutics. 2018-2-27

[5]
Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review.

Pharmaceutics. 2018-1-13

[6]
Steroid-induced Glaucoma: An Avoidable Irreversible Blindness.

J Curr Glaucoma Pract. 2017

[7]
Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation.

AAPS PharmSciTech. 2017-4-20

[8]
A comprehensive insight on ocular pharmacokinetics.

Drug Deliv Transl Res. 2016-12

[9]
Prodrug approach to improve absorption of prednisolone.

Int J Pharm. 2015-6-20

[10]
Ocular drug delivery systems: An overview.

World J Pharmacol. 2013

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索